Akero announced today two #EFX updates at #EASLCongress 2024: a late-breaking analysis of the Week 96 results of the Phase 2b HARMONY trial and a post-hoc biomarker analysis showing the anti-fibrotic effects of EFX in patients with #MASH fibrosis F2-F3. Learn more here: https://lnkd.in/exrQk-d9. #EASL
Akero Therapeutics’ Post
More Relevant Posts
-
Our recent study presented during NASH Tag 2024, aims to retrospectively compare the efficacy of two combinations in one-step approach with two biomarkers, LiverSTAT and LSM (Liver Stiffness Measurement) versus FIB-4 and LSM for the identification of advanced fibrosis (F3F4) in a multicenter-multiethnic dataset of MASLD patients. The study demonstrated the one-step assessment of MASLD-related fibrosis using the combination LiverSTAT and Fibroscan: • Correctly identified twice as many F3F4 patients than the combination of FIB-4 and Fibroscan • Does not miss F3F4 patients because of a “grey zone” • Moreover, can help to detect 41% of F3F4 missed cases by FIB-4 “grey zone” • Had a high concordance rate to rule in/out advanced fibrosis and, therefore, can work as an upfront screening for F3F4 before referral to more complex assessments Find out more: https://lnkd.in/gyD2QEpp #LIVERSTAT #fibrostudies #MASLD
To view or add a comment, sign in
-
-
Mark your calendar! Join us for the next installment in our Emerging and Evolving Biomarkers series, “TP53 Mutations in Myeloid Neoplasms,” on June 20 at 11 AM ET: https://ow.ly/yf6i50S6RGm #molpath #pathologists
To view or add a comment, sign in
-
-
Join me and Dr Hanan today for an interesting discussion about novel blood based biomarkers for the diagnosis of Alzheimer’s Disease as well as breakthrough advances in treating the disease
Join our experts for the first session of the National Reference Laboratory (NRL) #FocusOnseries! Dr. Fatma Ridene, Dr. Laila AbdelWareth, and Dr. Hanan Ibrahim take a deep dive into Alzheimer’s diagnostics, focusing on risk factors, novel biomarkers, and exploring innovative therapeutic interventions. Get in-depth insights on Wednesday, August 7th, from 3–4 PM. Register today: https://bit.ly/4fr0Pgh
To view or add a comment, sign in
-
-
Jennifer Herrera-Mullar, MGC, LCGC, discusses the takeaway points of one of Ambry’s poster presentations at #CGC2024. This summary explores two important aspects of gene-disease validity curation: how scoring methods have evolved over time and how GDV impacts the clinical utility of multi-gene panel testing. Watch the video to find out what trends they discovered. #genetictesting #hereditarycancer #variantclassification
To view or add a comment, sign in
-
OMPRN is excited to share with you our new 'understanding biomarkers' graphic series. Here is the 4th biomarker: Therapeutic Biomarkers! Terms you should know: ✨ Biomarker - A biological molecule found in blood, other body fluids, or tissues that is a sign of a normal or abnormal process, or of a condition or disease. A biomarker may be used to see how well the body responds to a treatment for a disease or condition. Also called molecular marker and signature molecule. Be sure to keep an eye out for the rest of the series and to consult our website for our enhanced glossary as well as some more resources! #cancereducation #biomarkers #understandingbiomarkers
To view or add a comment, sign in
-
-
May is #MelanomaAwarenessMonth. There is an unmet medical need within a subgroup of #Melanoma #SkinCancer patients, demanding an increase in global BRAF biomarker testing for this group. A thorough understanding of the patient journey is essential to overcoming this barrier. Learn more in this recent IQVIA Institute report: https://lnkd.in/evD3fJcn
To view or add a comment, sign in
-
-
Good morning ! The first lecture of the day….#IAPRD2024 Lisbon, Portugal Aniti-alpha synuclein and anti-tau immunotherapies: Can a cocktail approach work ? By Yaroslau Compta Highlights • a-synuclein and 4R-tau aggregates often coexist in synucleinopathies and tauopathies. • Anti-Synuclein and anti-tau immunotherapies are being tested in clinical trials. • Increasingly reliable biomarkers foreseeably will allow to assess in vivo co-pathologies. • A cocktail immunotherapy targeting both a-synuclein and 4R-tau is conceivable. Full article: https://lnkd.in/gJ4wwawX IAPRD Secretariat
To view or add a comment, sign in
-
-
Struggling to diagnose periprosthetic joint infections (PJI) in hips and knees? Discover the latest methods and breakthroughs in PJI diagnostics. Explore evidence-based criteria, biomarkers, synovial fluid analysis, and next-generation sequencing for early detection. Stay ahead of the curve and provide better patient care. Read more in the study below. https://lnkd.in/eMAnrYxq #PJI #Diagnostics #MedicalResearch
To view or add a comment, sign in
-
-
May is #MelanomaAwarenessMonth. There is an unmet medical need within a subgroup of #Melanoma #SkinCancer patients, demanding an increase in global BRAF biomarker testing for this group. A thorough understanding of the patient journey is essential to overcoming this barrier. Learn more in this recent IQVIA Institute report: https://lnkd.in/dPN524WF
To view or add a comment, sign in
-
Head of Project Management at Ashvattha Therapeutics
2moFantastic update!